SCHEMBL22170249

SCHEMBL22170249

N#C[C@@H]1C[C@@H](O)[C@@H](O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18963556 1.00
SCHEMBL14205388 0.81
SCHEMBL18603115 0.81
SCHEMBL18581293 0.81
SCHEMBL14737560 0.80
SCHEMBL2297447 0.80
SCHEMBL20673187 0.80
SCHEMBL29771365 0.78
SCHEMBL28823871 0.78
SCHEMBL22260165 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3674409-A1 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TMPRSS6 GENE Alnylam Pharmaceuticals, Inc. (US) 2020-07-01 EP disclosed
EP-2723758-B1 ANGIOPOIETIN-LIKE 3 (ANGPTL3) IRNA COMPOSTIONS AND METHODS OF USE THEREOF ALNYLAM PHARMACEUTICALS INC (US) 2018-06-20 EP disclosed
EP-2836595-B1 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE ALNYLAM PHARMACEUTICALS INC (US) 2017-06-14 EP disclosed